Scinai Immunotherapeutics Ltd.

JERUSALEM, L3 · CIK 0001611747 · Biotech · Public

Innovative immunology and infectious disease biologics, plus contract development and manufacturing organization (CDMO) services

scinai.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$3.0M
2 Form D · Jan 2024
33 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,329,254
Private capital raisedForm D · SEC$1,694,259
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2141ImmunoMolecular Therapeutics, Inc.—$11M
2142CELLECHO INC——
2143Calico——
2144Scinai Immunotherapeutics Ltd.—$3.0M
2145ISOLERE BIO INC——
2146Origin Life Sciences, Inc.—$2.9M
2147KALION, INC.—$6.7M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 11 related persons
  • Uri Ben OrExecutive Officer
  • Tamar Ben-YedidiaExecutive Officer
  • Mark GermainDirector
  • Jay GreenDirector
  • Morris LasterDirector
  • Yael MargolinDirector
  • Elad MarkExecutive Officer
  • Samuel MoedDirector
  • Adi RavivDirector
  • Amir ReichmanDirector · Executive Officer
  • Avner RotmanDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.